5-Amino-1MQ vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Also: AM833, NN9838
A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Cagrilintide has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | 5-Amino-1MQ | Cagrilintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | 5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake. | Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness. |
| Common Dosing | 50-75 mg daily Once daily, morning | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection or oral | Subcutaneous injection once weekly |
| Typical Duration | 4-6 weeks (cycling recommended) | Long-term / chronic use expected |
| Best Time to Take | Morning, fasted | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited. | REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication. |
Frequently Asked Questions: 5-Amino-1MQ vs Cagrilintide
What is the difference between 5-Amino-1MQ and Cagrilintide?
5-Amino-1MQ is a weight loss peptide that a selective nnmt (nicotinamide n-methyltransferase) inhibitor that enhances cellular energy metabolism. not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support. Cagrilintide is a weight loss peptide that a long-acting amylin analog developed by novo nordisk for obesity treatment. works through a different mechanism than glp-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. shows enhanced weight loss when combined with semaglutide (cagrisema). The main differences lie in their mechanisms of action and clinical applications.
Which is better, 5-Amino-1MQ or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. 5-Amino-1MQ is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can 5-Amino-1MQ and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using 5-Amino-1MQ and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of 5-Amino-1MQ and Cagrilintide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.